Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | HCK | P08631 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 2/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777139 | 1.00 | KDR (0.44) | KDRPIK3CAPIK3CDABL1EGFR | |
| SCHEMBL1750249 | 0.90 | CA12 (0.44) | KDRPIK3CAPIK3CDABL1EGFR | |
| SCHEMBL17782610 | 0.88 | EGFR (0.40) | KDRPIK3CAPIK3CDABL1EGFR | |
| SCHEMBL27700200 | 0.84 | KDR (0.42) | KDRPIK3CAPIK3CDABL1EGFR | |
| SCHEMBL2266733 | 0.83 | TUBB1 (0.55) | KDRPIK3CAPIK3CDABL1EGFR | |
| SCHEMBL30230816 | 0.83 | TUBB1 (0.55) | KDRPIK3CAPIK3CDABL1EGFR | |
| SCHEMBL17061440 | 0.81 | PIK3CD (0.44) | KDRPIK3CAPIK3CDABL1EGFR | |
| SCHEMBL3839289 | 0.81 | TFPI2 (0.51) | KDRPIK3CAPIK3CDABL1EGFR | |
| SCHEMBL1372514 | 0.81 | ELANE (0.47) | KDRPIK3CAPIK3CDABL1EGFR | |
| SCHEMBL29992081 | 0.81 | PIK3CD (0.44) | KDRPIK3CAPIK3CDABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334285-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | Kare Chemical Technologies Inc. (CA) | 2024-03-13 | — | — | EP | disclosed |
| CN-117597329-A | Method for the catalytic synthesis of tryptamine and precursors thereof | 凯尔化学科技公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2022232931-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2018-08-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20040002501-A1 | Orally active salts with tyrosine kinase activity | FRALEY MARK E (US) | 2004-01-01 | — | — | US | disclosed |
| US-6656942-B2 | For therapy of diseases such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals | MERCK & CO., INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1328519-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2003020699-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-1226136-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | MERCK & CO., INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2002032861-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001029025-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002501-A1 | Orally active salts with tyrosine kinase activity | TEK, FLT1, TIE1 | KDR 5/4885PIK3CA 357/4885PIK3CD 450/4885 |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | KDR 1088/4885PIK3CA 396/4885PIK3CD 509/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | KDR 1813/4885PIK3CA 521/4885PIK3CD 460/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | KDR 1813/4885PIK3CA 521/4885PIK3CD 460/4885 |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | TEK, FLT1, TIE1 | KDR 5/4885PIK3CA 357/4885PIK3CD 450/4885 |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | KDR 1813/4885PIK3CA 521/4885PIK3CD 460/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | KDR 318/4885PIK3CA 2099/4885PIK3CD 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.